Submitted by Anonymous (not verified) on 5 April 2024 - 13:10
Opinion/decision on a Paediatric investigation plan (PIP): Keytruda, Pembrolizumab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Oncology, PIP number: P/0096/2023
Source: